Diagnósticos da América : Dasa posted double-digit EBITDA growth and closed its transformative joint venture with Amil

About this update from Diagnosticos Da America S.a.

Dasa delivered strong 1Q25 results with 11% EBITDA growth, margin expansion, and reduced net loss, while closing a major joint venture with Amil and maintaining disciplined capital allocation. Leverage and liquidity remain stable, supporting long-term value creation.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Diagnosticos Da America S.a.